En español
NIDA

NIDA Notes Articles: Buprenorphine

NIDA Notes Category Graphic

Dr. Evan D. Kharasch Joins the Institute of Medicine

December 2013
Dr. Kharasch is a NIDA-funded researcher known for a broad range of research into how drugs are metabolized in the body.

NIDA Notes Category Graphic

Gene Variants Reduce Opioid Risks

June 2014
Two recent studies suggest that genotyping may enable clinicians to base therapies on individual patients’ potential responsiveness to opioid drugs’ therapeutic effects and vulnerability to their harmful effects.

NIDA Notes Category Graphic

Patients Addicted to Opioid Painkillers Achieve Good Results With Outpatient Detoxification

February 2015
A significant portion of individuals who are addicted to opioid painkillers may initiate and maintain abstinence with a brief but intensive outpatient detoxification treatment followed by opioid antagonist therapy using naltrexone.

NIDA Notes Category Graphic

Study Points to Individualized Therapy for Opioid Addiction

February 2015
Trial participants who were addicted to opioid painkillers and did not inject drugs stayed in treatment longer and achieved better outcomes than those who were addicted to heroin or injected drugs.

NIDA Notes Category Graphic

Long-Term Follow-Up of Medication-Assisted Treatment for Addiction to Pain Relievers Yields “Cause for Optimism”

November 2015
In the first long-term follow-up of patients treated with buprenorphine/naloxone for addiction to opioid pain relievers, half reported that they were abstinent from the drugs 18 months after starting the therapy.

NIDA Notes Category Graphic

ED-Initiated Buprenorphine Outperforms Referral or SBIRT for ED Patients With Opioid Addiction

January 2016
Emergency department visits present prime opportunities to identify people with opioid addiction and provide them with onsite initiation of treatment with buprenorphine/naloxone.

NIDA Notes Category Graphic

Dual Regimen Aims To Shorten Medication-Assisted Therapy

May 2016
Treatment that combines use of Bp/Nx and memantine may enable young adults addicted to opioids establish lasting abstinence after a relatively brief course of medication-assisted therapy, a pilot trial suggests.

NIDA Notes Category Graphic

Buprenorphine Benefits Waitlisted Seekers of Opioid Treatment

March 2017
In two pilot clinical trials, buprenorphine helped participants reduce their illicit opioid use and injection drug use while awaiting admission to a methadone or buprenorphine treatment program. Researchers minimized the risks for improper use or diversion of the study medication by giving it to trial participants in a computerized, tamper-proof device that dispenses one dose each day.

Pages

NIDA Notes

Tags

Drug Topics

Drugs of Abuse

Population Groups

Related Topics